



Media statement

GSK received a letter from the Arab Company for Drug Industries & Medical Appliances (Acdima) in which Acdima expressed a desire for the acquisition of our shares in the GlaxoSmithKline SAE and requested the grant of access to carry out due diligence.

Additionally, following the termination of discussions with Hikma communicated to the Egypt Exchange on March 11, GlaxoSmithKline SAE informed the Egypt Exchange that GlaxoSmithKline Group Limited (GGL) communicated to the board of directors of GSK SAE that the company is not willing to sell its shares in GSK SAE and therefore is not engaging in any sale process with any party at this time. The board of directors will meet on Sunday to discuss this matter and will announce its decision on Monday, March 15, 2021.

In the communication sent to GSK SAE, GlaxoSmithKline Group Limited expressed that the company's immediate focus in the changed circumstances is stabilising its operations in Egypt and ensuring the supply of medicines and CH products to patients.

Patients and consumers are the number one priority for our company, therefore making sure our business is fully operative will safeguard any disruption in the delivery of medicines and products to people who need them the most.

As part of our aspiration to become a leading and growing global biopharma company, protecting and improving more lives every day and a world-leading Consumer Healthcare company – delivering better everyday health –GSK will continue to review our operations to deliver our strategic priorities. And, as we always do, we will act in line with our values, patient focus, transparency, respect and integrity.

End